Wellington Management Group’s Avidity Biosciences RNAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-723,118
Closed -$52.2M 1987
2025
Q4
$52.2M Sell
723,118
-9,342,069
-93% -$603M 0.01% 726
2025
Q3
$439M Buy
10,065,187
+815,497
+9% +$33M 0.08% 225
2025
Q2
$263M Sell
9,249,690
-434,866
-4% -$13M 0.05% 301
2025
Q1
$286M Buy
9,684,556
+1,578,459
+19% +$49.2M 0.06% 267
2024
Q4
$236M Buy
8,106,097
+1,075,148
+15% +$44.9M 0.04% 333
2024
Q3
$323M Buy
7,030,949
+3,228,923
+85% +$140M 0.06% 285
2024
Q2
$155M Buy
3,802,026
+2,573,028
+209% +$73.8M 0.03% 440
2024
Q1
$31.4M Buy
1,228,998
+937,780
+322% +$14.7M 0.01% 838
2023
Q4
$2.64M Buy
291,218
+43,147
+17% +$288K ﹤0.01% 1436
2023
Q3
$1.58M Buy
248,071
+12,835
+5% +$111K ﹤0.01% 1518
2023
Q2
$2.61M Buy
235,236
+91,366
+64% +$1.15M ﹤0.01% 1430
2023
Q1
$2.21M Buy
143,870
+5,461
+4% +$120K ﹤0.01% 1491
2022
Q4
$3.07M Sell
138,409
-59,884
-30% -$893K ﹤0.01% 1394
2022
Q3
$3.24M Sell
198,293
-869,930
-81% -$16.6M ﹤0.01% 1400
2022
Q2
$15.5M Sell
1,068,223
-67,521
-6% -$1M ﹤0.01% 1011
2022
Q1
$21M Buy
1,135,744
+112,024
+11% +$1.9M ﹤0.01% 1003
2021
Q4
$24.3M Buy
1,023,720
+414,457
+68% +$9.9M ﹤0.01% 1029
2021
Q3
$15M Buy
609,263
+141,807
+30% +$3.08M ﹤0.01% 1157
2021
Q2
$11.6M Buy
467,456
+151,445
+48% +$3.52M ﹤0.01% 1228
2021
Q1
$6.89M Sell
316,011
-225,404
-42% -$5.52M ﹤0.01% 1348
2020
Q4
$13.8M Sell
541,415
-206,692
-28% -$6.03M ﹤0.01% 1104
2020
Q3
$21.1M Sell
748,107
-126,981
-15% -$3.67M ﹤0.01% 944
2020
Q2
$24.7M Buy
+875,088
New +$25.2M 0.01% 880

Other funds holding RNAM

Wellington Management Group's RNAM Position: Q1 2026 in Review

Wellington Management Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 723,118 shares — an estimated $52.2M sold.

Wellington Management Group first reported a position in RNAM in Q2 2020 and held it in 23 quarters. The position peaked at $439M in Q3 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Wellington Management Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Wellington Management Group sold 723,118 Avidity Biosciences shares in Q1 2026, an estimated $52.2M.
  • Wellington Management Group first reported a position in Avidity Biosciences in Q2 2020 and held it in 23 quarters.
  • Wellington Management Group's Avidity Biosciences position peaked at $439M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Wellington Management Group's 13F filing for Q1 2026, filed 15 May 2026.